Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hayakazu Sumida

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Rheumatology (Oxford, England)|February 28, 2013
A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune responseYuri Masui, Yoshihide Asano, Sayaka Shibata, et al.
Journal of Pharmacological Sciences|February 8, 2018
LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse modelRyoko Tsukahara, Shinji Yamamoto, Keisuke Yoshikawa, et al.
The Journal of Dermatology|October 6, 2018
Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational studyHayakazu Sumida, Yoshihide Asano, Zenshiro Tamaki, et al.
The Journal of Dermatology|July 28, 2018
Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung diseaseHiroko Numajiri, Ayumi Yoshizaki, Takemichi Fukasawa, et al.
Rheumatology International|October 22, 2013
Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosisYuri Masui, Yoshihide Asano, Kaname Akamata, et al.
Rheumatology (Oxford, England)|December 26, 2014
Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosisKaname Akamata, Yoshihide Asano, Takashi Taniguchi, et al.
Frontiers in Immunology|May 6, 2026
Biomarker-based clustering identifies distinct pulmonary function trajectories in early systemic sclerosisSaori Uesugi-Uchida, Yoshihide Asano, Hirahito Endo, et al.
Modern Rheumatology|May 22, 2012
Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosisYuri Masui, Yoshihide Asano, Takehiro Takahashi, et al.
The Journal of Dermatology|February 28, 2015
Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosisRyosuke Saigusa, Yoshihide Asano, Kouki Nakamura, et al.
Digestion|July 26, 2018
Gastroesophageal Reflux Disease-Related Disorders of Systemic Sclerosis Based on the Analysis of 66 PatientsRie Matsuda, Nobutake Yamamichi, Takeshi Shimamoto, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Rheumatology (Oxford, England)|February 28, 2013
A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune responseYuri Masui, Yoshihide Asano, Sayaka Shibata, et al.
Journal of Pharmacological Sciences|February 8, 2018
LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse modelRyoko Tsukahara, Shinji Yamamoto, Keisuke Yoshikawa, et al.
The Journal of Dermatology|October 6, 2018
Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational studyHayakazu Sumida, Yoshihide Asano, Zenshiro Tamaki, et al.
The Journal of Dermatology|July 28, 2018
Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung diseaseHiroko Numajiri, Ayumi Yoshizaki, Takemichi Fukasawa, et al.
Rheumatology International|October 22, 2013
Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosisYuri Masui, Yoshihide Asano, Kaname Akamata, et al.
Rheumatology (Oxford, England)|December 26, 2014
Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosisKaname Akamata, Yoshihide Asano, Takashi Taniguchi, et al.
Frontiers in Immunology|May 6, 2026
Biomarker-based clustering identifies distinct pulmonary function trajectories in early systemic sclerosisSaori Uesugi-Uchida, Yoshihide Asano, Hirahito Endo, et al.
Modern Rheumatology|May 22, 2012
Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosisYuri Masui, Yoshihide Asano, Takehiro Takahashi, et al.
The Journal of Dermatology|February 28, 2015
Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosisRyosuke Saigusa, Yoshihide Asano, Kouki Nakamura, et al.
Digestion|July 26, 2018
Gastroesophageal Reflux Disease-Related Disorders of Systemic Sclerosis Based on the Analysis of 66 PatientsRie Matsuda, Nobutake Yamamichi, Takeshi Shimamoto, et al.
Pageof 6